These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28741691)

  • 21. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
    Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
    Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
    Risdon RA; Barry M; Flynn DM
    J Pathol; 1975 Jun; 116(2):83-95. PubMed ID: 1151528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life and life expectancy in thalassemic patients with complications.
    Gabutti V; Piga A; Sacchetti L; Sandri A; Biginelli M; Saracco P; Ferri M
    Prog Clin Biol Res; 1989; 309():35-41. PubMed ID: 2780748
    [No Abstract]   [Full Text] [Related]  

  • 25. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical management of beta-thalassemia.
    Lerner N
    Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
    [No Abstract]   [Full Text] [Related]  

  • 27. [Iron chelation in children].
    de Montalembert M; Guillemot F; Clairicia M; Girot R
    Ann Pediatr (Paris); 1989 Oct; 36(8):533-8. PubMed ID: 2683951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Patient compliance in iron-chelating therapy of beta-thalassemia major].
    Di Gregorio F; Romeo MA; Tasca R; Passaniti G
    Minerva Pediatr; 1983 May; 35(10):489-93. PubMed ID: 6877194
    [No Abstract]   [Full Text] [Related]  

  • 29. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
    Chang HH; Lu MY; Peng SS; Yang YL; Lin DT; Jou ST; Lin KH
    Ann Hematol; 2015 Dec; 94(12):1945-52. PubMed ID: 26404899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 31. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 32. Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia.
    Ricchi P; Meloni A; Costantini S; Spasiano A; Di Matola T; Pepe A; Cinque P; Filosa A
    Ann Hematol; 2017 Sep; 96(9):1541-1546. PubMed ID: 28707012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI and iron-overload cardiomyopathy in thalassaemia.
    Pennell D
    Circulation; 2006 Mar; 113(11):f43-4. PubMed ID: 16552847
    [No Abstract]   [Full Text] [Related]  

  • 34. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
    Kattamis C; Lagos P; Langona E
    Prog Clin Biol Res; 1979; 34():351-9. PubMed ID: 531060
    [No Abstract]   [Full Text] [Related]  

  • 35. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 36. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
    Pongtanakul B; Viprakasit V
    Blood Cells Mol Dis; 2013 Aug; 51(2):96-7. PubMed ID: 23566753
    [No Abstract]   [Full Text] [Related]  

  • 37. [Height-weight growth in homozygous beta-thalassemia in relation to transfusional regime].
    Miniero R; Sacchetti L; Isolato V
    Minerva Pediatr; 1977 Jan; 29(1):73-80. PubMed ID: 840203
    [No Abstract]   [Full Text] [Related]  

  • 38. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High nontransferrin bound iron levels and heart disease in thalassemia major.
    Piga A; Longo F; Duca L; Roggero S; Vinciguerra T; Calabrese R; Hershko C; Cappellini MD
    Am J Hematol; 2009 Jan; 84(1):29-33. PubMed ID: 19006228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron chelation.
    Hershko C; Link G; Pinson A
    Prog Clin Biol Res; 1989; 309():133-40. PubMed ID: 2675082
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.